DrugPatentWatch Database Preview
ZIDOVUDINE - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic sources for zidovudine and what is the scope of freedom to operate?
Zidovudine
is the generic ingredient in two branded drugs marketed by Viiv Hlthcare, Aurobindo Pharma Ltd, Cipla Ltd, Liaoning Chengda, Luitpold, Aurobindo, Aurobindo Pharma, Cipla, Hec Pharm, Hetero Labs Ltd Iii, Hikma, Matrix Labs Ltd, Mylan Pharms Inc, and Ranbaxy Labs Ltd, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.There are twenty-two drug master file entries for zidovudine. Eight suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for ZIDOVUDINE
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 14 |
| NDAs: | 19 |
| Drug Master File Entries: | 22 |
| Suppliers / Packagers: | 8 |
| Bulk Api Vendors: | 76 |
| Clinical Trials: | 487 |
| Patent Applications: | 4,294 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for ZIDOVUDINE |
| DailyMed Link: | ZIDOVUDINE at DailyMed |
Recent Clinical Trials for ZIDOVUDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Médecins Sans Frontières, Belgium | Phase 4 |
| University of Cape Town | Phase 4 |
| Infectious Diseases Institute, Uganda | Phase 3 |
Generic filers with tentative approvals for ZIDOVUDINE
| Applicant | Application No. | Strength | Dosage Form |
| Start Trial | Start Trial | 100MG | CAPSULE; ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for ZIDOVUDINE
| Drug Class | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor |
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Medical Subject Heading (MeSH) Categories for ZIDOVUDINE
Synonyms for ZIDOVUDINE
| (AZT) 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione |
| (AZT)1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione |
| 1-((2R,4R,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione |
| 1-((2R,4S,5S)-4-(diazoamino)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione |
| 1-((2R,4S,5S)-4-azido-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione |
| 1-((2R,4S,5S)-4-AZIDO-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE |
| 1-((2R,4S,5S)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione |
| 1-((2R,5S)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione |
| 1-((2S,4R,5R)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione |
| 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)-5-methylpyrimidine-2,4-(1H,3H)-dione |
| 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (AzddThd, AZT) |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (AZT) |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (N3ddThd) |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione [AZT] |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(3''-azido-2'',3''-dideoxythymidine) |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(azidothymidine, AZT) |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(AZT) |
| 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(Zidovudine, AZT) |
| 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione |
| 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione |
| 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione |
| 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione |
| 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione |
| 3-((2S,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)triaz-1-en-2-ium-1-ide |
| 3-Azido-1,2,3-trideoxy-1-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-D-erythro- pentofuranuronic acid |
| 3-Azido-3-deoxythymidine |
| 3'-Azido-2',3'-Dideoxythymidine |
| 3'-Azido-2',3'-dideoxythymidine & sCD4(soluble recombinant protein) |
| 3'-Azido-3'-deoxythymidine |
| 3'-Azido-3'-deoxythymidine (AIDS) |
| 3'-Azido-3'-deoxythymidine & CD4-Pseudomonas exotoxin A hybrid |
| 3'-Azido-3'-deoxythymidine & Concanavalin A |
| 3'-Azido-3'-deoxythymidine & Erythropoietin |
| 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19 |
| 3'-Azido-3'-deoxythymidine & Interleukin-1 |
| 3'-Azido-3'-deoxythymidine & Interleukin-2 |
| 3'-Azido-3'-deoxythymidine & Interleukin-6 |
| 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin |
| 3'-Azido-3'-deoxythymidine & Lithium & Granulocyte-macrophage colony-stimulating factor |
| 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1 |
| 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6 |
| 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon |
| 3'-Azido-3'-deoxythymidine & Recombinant Interferon-.alpha.-2 |
| 3'-Azido-3'-deoxythymidine & Sho-Saiko-To |
| 3'-Azido-3'-deoxythymidine, >=98% (HPLC) |
| 3'-Azido-3'-deoxythymidine, >=99.0% (HPLC) |
| 3'-azido-3'-deoxythymidine, AZT |
| 3'-Azido-3'deoxythymidine & Interferon .alpha. |
| 3'-Azido-3'deoxythymidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate) |
| 3'-Azido-3'deoxythymidine & Recombinant Soluble CD4 & Recombinant Interferon.alpha.A |
| 3'-azido3'-deoxythymidine |
| 3'-deoxy-3'-azido-thymidine |
| 3'-Deoxy-3'-azidothymidine |
| 3''-azido-2'',3''-dideoxythymidine |
| 3''-Azido-3''-deoxy-thymidine |
| 3''-azido-thymidine |
| 3''-Deoxy-3-azidothymidine |
| 3''azido-2''3''-dideoxythymidine |
| 3'azido-3'deoxythymidine |
| 3′-Azido-3′-deoxythymidine |
| 30516-87-1 |
| 399024-19-2 |
| 4-(4-Azido-5-hydroxy-tetrahydro-furan-2-yl)-5-methyl-3H-pyrazine-2,6-dione |
| 4B9XT59T7S |
| 4lhm |
| AB0012841 |
| AC1L1TKL |
| AC1Q2OEK |
| AEe paragraph signa.o paragraph sign |
| AKOS005622576 |
| AKOS015842610 |
| ANW-26899 |
| Apo-Zidovudine |
| AS-13019 |
| Azidothymidine |
| Azidothymidine; Zidovudine |
| AZT |
| AZT (Antiviral) |
| AZT & CD4(178)-PE 40 |
| AZT & Colony-stimulating factor 2 |
| AZT & Concanavalin A (ConA) |
| AZT & EPO |
| AZT & GM-CSF |
| AZT & HPA |
| AZT & IFN.alpha. |
| AZT & IFNL1 |
| AZT & IFNL2 |
| AZT & IFNL3 |
| AZT & IL-1 |
| AZT & IL-2 |
| AZT & IL-28A |
| AZT & IL-28B |
| AZT & IL-29 |
| AZT & IL-6 |
| AZT & Interferon lambda-1 |
| AZT & Interferon lambda-2 |
| AZT & Interferon lambda-3 |
| AZT & Interferon-.alpha.-2 |
| AZT & Interleukin 28A |
| AZT & Interleukin 28B |
| AZT & Interleukin 29 |
| AZT & Li & EPO |
| AZT & Li & GM-CSF |
| AZT & Li & IL-1 |
| AZT & Li & IL-6 |
| AZT & Lymphoblastoid Interferon |
| AZT & NP (from PHCA or HSA) |
| AZT & PM-19 |
| AZT & rIFN.alpha.2 |
| AZT & rsCD4 & rIFN.alpha.A |
| AZT & rsT4 |
| AZT & sCD4 |
| AZT & srCD4 |
| AZT & SST |
| AZT Antiviral |
| AZT TRANSPLACENTAL CARCINOGENESIS STUDY |
| AZT, Antiviral |
| AZT+PRO 140 |
| Aztec |
| BBL033764 |
| BDBM50002692 |
| Beta interferon(rIFN-beta seron) & 3'-Azido-3'-deoxythymidine(AZT) |
| BPBio1_000403 |
| BRD-K72903603-001-04-6 |
| BRD-K72903603-001-14-5 |
| BSPBio_000365 |
| BSPBio_003153 |
| BW A509U |
| BW-A 509U |
| BW-A-509U |
| BW-A509U |
| BWA-509U |
| BWA509U |
| C07210 |
| CCG-39924 |
| CCRIS 105 |
| CHEBI:10110 |
| CHEMBL129 |
| Compound S |
| Cpd S |
| CPD000058351 |
| CTK4I2082 |
| CZ0012 |
| D00413 |
| DB00495 |
| DivK1c_000524 |
| DRG-0004 |
| DS-4152 & AZT |
| DSSTox_CID_127 |
| DSSTox_GSID_20127 |
| DSSTox_RID_75386 |
| DTXSID8020127 |
| EN300-52518 |
| FT-0601543 |
| GTPL4825 |
| HBOMLICNUCNMMY-XLPZGREQSA-N |
| HMS1921J20 |
| HMS2090G11 |
| HMS2092D06 |
| HMS2096C07 |
| HMS2234K17 |
| HMS3259H17 |
| HMS3713C07 |
| HMS501K06 |
| HSDB 6515 |
| IDI1_000524 |
| Interferon AD + 3'-azido-3'-deoxythymidine |
| Intron A & AZT |
| J-700147 |
| J10271 |
| K7 [P Ti2 W10 O40] |
| KBio1_000524 |
| KBio2_001828 |
| KBio2_004396 |
| KBio2_006964 |
| KBio3_002653 |
| KBioGR_000703 |
| KBioSS_001828 |
| KS-00000WOF |
| Lecithinized superoxide dismutase & Thymidine, 3'-azido-3'-deoxy- |
| Liposomal AZT-SN-1 |
| Liposomal AZT-SN-3 |
| LS-1159 |
| MCULE-8664408343 |
| Met-SDF-1.beta. & AZT |
| Met-SDF-1.beta. & Zidovudine |
| Met-Stromal Cell-derived Factor-1.beta. (Human) & 3'-Azido-3'-deoxythymidine |
| MFCD00006536 |
| microthornmicro feminineEthOUO |
| MLS000028548 |
| MLS001055351 |
| MLS001076358 |
| MLS002153202 |
| MLS002222249 |
| MolPort-002-507-286 |
| NC00666 |
| NCGC00014918-01 |
| NCGC00023945-03 |
| NCGC00023945-04 |
| NCGC00023945-05 |
| NCGC00023945-06 |
| NCGC00023945-07 |
| NCGC00023945-08 |
| NCGC00023945-09 |
| NCGC00023945-10 |
| NCGC00023945-12 |
| NCGC00023945-13 |
| NCGC00178237-01 |
| NCGC00178237-02 |
| NCGC00254276-01 |
| NCGC00259752-01 |
| NINDS_000524 |
| Novo-Azt |
| NSC 602670 |
| NSC-758185 |
| NSC758185 |
| Opera_ID_1602 |
| PC-SOD+AZT |
| Pharmakon1600-01502109 |
| Prestwick3_000333 |
| Propolis & Thymidine, 3'-azido-3'-deoxy- |
| Propolis+AZT |
| Racemic Liposomal AZT |
| racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle) |
| Retrovir |
| Retrovir (TN) |
| Retrovir(TM) |
| rIFN-beta seron & AZT |
| S2579 |
| SAM002548971 |
| SBI-0051731.P002 |
| SCHEMBL14615088 |
| SMR000058351 |
| SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle) |
| SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle) |
| SPBio_000834 |
| Spectrum_001348 |
| SPECTRUM1502109 |
| Spectrum2_000927 |
| Spectrum3_001507 |
| Spectrum4_000332 |
| Spectrum5_001101 |
| SR-01000000098 |
| SR-01000000098-3 |
| SR-05000001587 |
| SR-05000001587-1 |
| STK801891 |
| Sulfated polysaccharide-peptidoglycan DS-4152 & 3'-Azido-3'-deoxythymidine |
| SW198799-2 |
| Thymidine, 3'-azido-3'-deoxy- |
| Thymidine, 3'-azido-3'-deoxy- & PRO 140 (Anti-CCR5 monoclonal antibody) |
| Tox21_110062 |
| Tox21_110062_1 |
| Tox21_110894 |
| Tox21_202203 |
| Tox21_300578 |
| UNII-4B9XT59T7S |
| W-5037 |
| Z1723414428 |
| ZDV |
| zidovudin |
| Zidovudina |
| Zidovudina [Spanish] |
| Zidovudine (JP17/USP/INN) |
| Zidovudine (Retrovir) |
| ZIDOVUDINE [AZT] |
| Zidovudine [USAN:INN:BAN:JAN] |
| Zidovudine [USAN:USP:INN:BAN:JAN] |
| Zidovudine & IFNL1 |
| Zidovudine & IFNL2 |
| Zidovudine & IFNL3 |
| Zidovudine & IL-28A |
| Zidovudine & IL-28B |
| Zidovudine & IL-29 |
| Zidovudine & Interferon lambda-1 |
| Zidovudine & Interferon lambda-2 |
| Zidovudine & Interferon lambda-3 |
| Zidovudine & Interleukin 28A |
| Zidovudine & Interleukin 28B |
| Zidovudine & Interleukin 29 |
| Zidovudine EP III |
| Zidovudine, European Pharmacopoeia (EP) Reference Standard |
| Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material |
| Zidovudine, United States Pharmacopeia (USP) Reference Standard |
| Zidovudine+PRO 140 |
| Zidovudinum |
| Zidovudinum [Latin] |
| ZINC3779042 |
| zudovidine |
| ZVD |
US Patents and Regulatory Information for ZIDOVUDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | RETROVIR | zidovudine | INJECTABLE;INJECTION | 019951-001 | Feb 2, 1990 | AP | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Aurobindo Pharma Ltd | ZIDOVUDINE | zidovudine | CAPSULE;ORAL | 078128-001 | Mar 27, 2006 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Luitpold | ZIDOVUDINE | zidovudine | INJECTABLE;INJECTION | 091457-001 | May 6, 2010 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Viiv Hlthcare | RETROVIR | zidovudine | SYRUP;ORAL | 019910-001 | Sep 28, 1989 | AA | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Cipla | ZIDOVUDINE | zidovudine | TABLET;ORAL | 090561-001 | Oct 27, 2010 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Matrix Labs Ltd | ZIDOVUDINE | zidovudine | TABLET;ORAL | 200732-001 | Feb 23, 2011 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZIDOVUDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-002 | Oct 4, 1996 | Start Trial | Start Trial |
| Viiv Hlthcare | RETROVIR | zidovudine | SYRUP;ORAL | 019910-001 | Sep 28, 1989 | Start Trial | Start Trial |
| Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-001 | Dec 19, 1995 | Start Trial | Start Trial |
| Viiv Hlthcare | RETROVIR | zidovudine | INJECTABLE;INJECTION | 019951-001 | Feb 2, 1990 | Start Trial | Start Trial |
| Viiv Hlthcare | RETROVIR | zidovudine | CAPSULE;ORAL | 019655-001 | Mar 19, 1987 | Start Trial | Start Trial |
| Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-002 | Oct 4, 1996 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2020 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.